302 results about "High risk group" patented technology

The subject disclosure presents systems and computer-implemented methods for assessing a risk of cancer recurrence in a patient based on a holistic integration of large amounts of prognostic information for said patient into a single comparative prognostic dataset. A risk classification system may be trained using the large amounts of information from a cohort of training slides from several patients, along with survival data for said patients. For example, a machine-learning-based binary classifier in the risk classification system may be trained using a set of granular image features computed from a plurality of slides corresponding to several cancer patients whose survival information is known and input into the system. The trained classifier may be used to classify image features from one or more test patients into a low-risk or high-risk group.

The subject disclosure presents systems and computer-implemented methods for providing reliable risk stratification for early-stage cancer patients by predicting a recurrence risk of the patient and to categorize the patient into a high or low risk group. A series of slides depicting serial sections of cancerous tissue are automatically analyzed by a digital pathology system, a score for the sections is calculated, and a Cox proportional hazards regression model is used to stratify the patient into a low or high risk group. The Cox proportional hazards regression model may be used to determine a whole-slide scoring algorithm based on training data comprising survival data for a plurality of patients and their respective tissue sections. The coefficients may differ based on different types of image analysis operations applied to either whole-tumor regions or specified regions within a slide.

The invention relates to a method and a device for rapidly and quantitatively detecting a tumor marker with an immunochromatography test strip marked by quantum dots. The method comprises the following steps of: replacing collaurum particles by using quantum dots as a signal marker, coupling with an antibody corresponding to the tumor marker to be tested, and spraying or directly coating on a conjugate releasing pad, wherein the antibody on another site corresponding to the tumor marker and a second antibody are coated on a nitrocellulose membrane to form a T line and a C line respectively; assembling a sample pad, a combining pad, a reaction membrane and a water absorbing pad according to a certain sequence to prepare the immunochromatography test strip; detecting qualitatively and quantitatively according to fluorescent stripes presented on the T line and the C line and the strength of fluorescence; and providing a quantum dot fluorescence immune detection device. The detection device is simple, the operation is simple and rapid, the time consumption for detection is short, and the result judgment is easy. The method and device are particularly suitable for early-stage screening, diagnosis, judgment prediction and prognosis of the tumor markers in households, communities, hospitals and the like, and evaluation of treatment effect and followed observation of high risk groups.

The invention discloses a male multi-tumor marker detection protein chip and a kit thereof. The chip comprises a substrate, protein markers distributed in an array type and point coatings of contrasts, wherein the substrate is a glass substrate or a film substrate; and the tumor markers and the point coatings of the contrasts are seven protein markers of AFP, CEA, NSE, CYFRA21-1, CA19-9, tPSA and SCC-ag, a positive contrast and a negative contrast which are uniformly distributed and latticed on the substrate. A reaction result of various indexes can be obtained only through one reaction by utilizing the protein chip, and the following tumors can be simultaneously screened: primary liver cancer, prostatic cancer, pancreatic cancer, lung cancer, esophageal cancer, gastric cancer and colorectal cancer. The invention is particularly suitable for the general examination of malignant tumors of male asymptomatic groups and high risk groups.

The present invention offers a comprehensive solution to care management which aggregates, integrates and stores clinical information from disparate sources. The system finds at-risk individuals before they experience preventable, high-cost medical events and stratifies high risk populations according to clinical criteria, which can include severity of disease states and co-morbidities. The system also compares the actual care an individual is receiving to established standards of clinical excellence and, if necessary, suggests pertinent medical care considerations to improve the care of medically mismanaged individuals. Another feature of the present invention may include a secure, patient-specific Web page which is automatically populated with a patient's own clinical information and can be personalized with customized, relevant healthcare information. The system allows users to design, facilitate and monitor clinical care plans and increase communications among physicians, nurses and patients. The system also predicts and analyzes the outcome of disease or case management for populations and individual patients.

The invention provides a probe set and a reagent kit used for detecting pathopoiesia / susceptibility genes of congenital megacolon and relative syndromes. At most 172 pathopoiesia / susceptibility genes related to diseases can be detected at the same time, and reference can be provided for affected individual molecular genetics diagnosis, mass survey of congenital megacolon high-incidence areas, screening of high-risk affected groups in congenital megacolon family members and corresponding genetic counseling or prenatal intervention.

The invention relates to a method for judging 2 type diabetes mellitus risk state and belongs to the technical field of biomedicine. The method includes that EM clusters and C4.5 classification are utilized to extract determinant attributes affecting attack of the 2 type diabetes mellitus, the crowd is divided into different cluster groups according to own characteristics, according to determinant attributes extracted results and a Logistic regression method, personal or crowd risk state is judged by combining metabolic syndrome and high risk group criterions. The determinant attributes affecting the 2 type diabetes mellitus are obtained, simultaneously, different risk state judgment models are built based on different characteristics of the crowd, the universality and practicability of the models are improved, the requirements of real-time processing and mobile computation are met, the effective degree of the determinant attributes is estimated through a quantitative analysis method, the complexity is low, the accuracy is high, and the divided risk state is detailed.

The invention discloses an intelligent voice-controlled voiceprint and face authentication access control system and a method. The system includes a gate host, an indoor host and a central server. Through voice control, the system avoids picking up the key, pressing button, checking fingerprint or other complex operation, especially the awkwardness for opening the door when items are held in the hands; the voiceprint and face recognition are combined to achieve a high security level, which is more secure than the traditional key, password lock and fingerprint lock. The access control system provided by the invention has basically the same shape and use method as the traditional visual intercom access control system and the visual doorbell, and is easy to be accepted by users; compared with the traditional visual intercom access control system and the visual doorbell, the access control system provided by the invention has additional no disturb function, which can be set aiming at the unwanted visitors like salesman. The access control system provided by the invention has community joint defense and linkage function, the control center can timely transfer high risk warning information, and control the host to automatically and timely warn high-risk groups (wanted suspects, etc.), so as to effectively avoid the occurrence of malignant cases, and protect the safety of the user's life and property.

Devices and methods for determining risk groups for patients according to their propensity to adhere to a medication prescription The “Adherence Estimator™” device of the present invention comprises an incremented scale of potential total scores, a prescription survey having questions directed to assessing a patient's beliefs in respect to no more than three domains, the three domains being commitment, concerns and cost, a response recording tool, a scoring matrix and an interpretation tool Embodiments of the invention, which may be implemented in electronic or non-electronic forms, automatically score and interpret responses to the prescription survey questions in order to determine and assign patients to a high risk group, a medium risk group or a low risk group Non-electronic devices of the invention may be constructed from a variety of materials, including without limitation, paper, paper-based products, plastic, wood or metal.

The invention relates to a method and a kit for diagnosing bladder cancer with urine. The invention discloses a group of methylated sensitive genes, comprising ECEL1, KCNV1, LMX1A, PROX1, SLC6A20, TAL1, TMEM 26, and VAXI gene. In urine samples of bladder cancer patients, the specific CpG sites of the genes are showed the highest methylation levels. Accordingly, the genes are the biological marker of bladder cancer. The method and the kit can be used as the basic of designing diagnostic reagents of bladder cancer, and are suitable for auxiliary detection of cancer in hospitals, postoperative followup, screening of high risk group of bladder cancer in community health centers, and screening of common people and high risk practitioners of bladder cancer in physical examination center.

The invention discloses an application method of long non-coding RNA (ribonucleic acid) (LncRNA) CASC2 originated from serum exosomes, namely the LncRNA CASC2 originated from the serum exosomes is used for preparing preparations for screening and early diagnosis of a high-risk group of gliomas or prognosis of patients with the gliomas. Studies prove that the expression level of the LncRNA CASC2 is reduced by extracting the RNA after separating the exosomes in serum of the patients with the gliomas, performing reverse transcription and performing real-time fluorescence quantitative analysis. By utilizing the LncRNA CASC2 originated from the serum exosomes, the specificity for early diagnosis of the gliomas can achieve 85.7% and the sensitivity can achieve 97.1%. By detecting the expression level of the LncRNA CASC2 in the serum exosomes of the patients with the gliomas, early and fast non-invasive diagnosis can be performed on the patients with the gliomas.

The embodiment of the invention provides a disease prediction method and device, a medium, and electronic equipment. The method comprises the steps: obtaining the data, correlated with health, of a plurality of users; carrying out the clustering analysis of the plurality of users based on the data, correlated with the health, of the users, so as to dividing the users into at least one class; determining a target class where a diagnosed patient belongs, and predicting other users in the target class as a high-risk group of diseases. According to the technical scheme of the invention, the methodcan achieve the prediction of the group which may have diseases, can guarantee the timely finding of severe diseases, so as to find and treat a disease early, and improve the level of health management of users.

The invention belongs to the technical field of rehabilitation medicine protection and particularly relates to a method for evaluating the balance capacity of old people. The method includes the following steps that A, experimental subjects are grouped into a normal group, a low-risk group, a middle-risk group and a high-risk group according an old people balance capacity test scale, plantar pressure distribution generated when the old people sit up is detected through a plantar pressure distribution detecting system, and cushion pressure generated when the old people sit up is detected through a cushion sensor; B, the old people walk on a three-dimensional dynamometry table, and kinematics parameters of the gaits generated when the old people walk are acquired through the three-dimensional dynamometry table, wherein the kinematics parameters comprise the pressure and torque in the foot vertical direction, the pressure and torque in the foot front-and-back direction and the pressure and torque in the foot inside and outside directions; C, sample entropies of the plantar pressure and torque during sitting up and walking are subjected to statistic analysis, the significant difference of the correlativity between the variable sample entropies is found, and an objective evaluation standard is obtained. The method has the advantage of being capable of evaluating dynamic balance of the old people.

The invention belongs to the technical field of cell immunity, and particularly relates to a preparation method of a human D-CIK (dendritic cell activated and cytokine induced killer) cell with high toxicity and high value-adding capacity. The preparation method comprises the following steps of 1) collecting peripheral venous blood so as to obtain a single karyocyte; 2) further separating the single karyocyte so as to obtain a mononuclear cell and a suspension cell; 3) induced differentiating the mononuclear cell to a mature DC (dendritic cell); 4) induced culturing CD3+CD8+CIK cells; 5) induced culturing the D-CIK cells so as to obtain a novel heterogeneity cell mass, i.e. D-CIK cells. Compared with the CIK cell, the value-adding activity and the cell toxic activity of the prepared D-CIK cell are stronger, and the prepared D-CIK cell also has the advantages of simple preparation process, low cost, and the like, and mass production is easy to realize. The prepared D-CIK cell is mainly used for treating cancer patients or preventing the cancer high-risk group.

The invention relates to a prognosis prediction model for patients with hilar cholangiocarcinoma. Specifically, the present invention provides a carrier for postoperative prognosis of patients with hilar cholangiocarcinoma, which is used to calculate risk factor scores and patient 3-year survival rate Y3 and / or 5-year survival rate Y5; Wherein, the risk factors include at least the patient's age X, and the fraction of the patient's age, the 3-year survival rate and the 5-year survival rate satisfy the relationship described in the article. The present invention systematically investigates the clinical and pathological characteristics that affect the prognosis of patients with hilar cholangiocarcinoma, and the effect of patients after surgical treatment, evaluates the key factors that affect the survival and prognosis of patients with hilar cholangiocarcinoma, and establishes a method for patients with hilar cholangiocarcinoma. The list of survival prognosis is used to evaluate the 3-year and 5-year survival rate of patients after surgery, and to screen out high-risk groups for intervention to improve the survival prognosis of patients.

The invention discloses a use of a recombinant mesenchymal stem cell in preparation of an immunosuppressant. The invention relates to the recombinant mesenchymal stem cell capable of expressing a chemokine receptor CCR7 on a cytomembrane. After infusion, the recombinant mesenchymal stem cells can be specifically transferred to a secondary lymphatic organ, and a large amount of the recombinant mesenchymal stem cells are gathered in a T cell enrichment region in the secondary lymphatic organ and can efficiently inhibit T cell immunoreaction. Through use of the recombinant mesenchymal stem cell in treatment on graft-versus-host disease after bone marrow transplantation, immunological rejection after organ transplantation and autoimmune diseases, a cost is reduced, a cell use amount is reduced and side-effects are relieved. In treatment, the recombinant mesenchymal stem cell retains tumor cell killing effects and provides a high efficiency and beneficial novel approach for clinical treatment on graft-versus-host disease after bone marrow transplantation, immunological rejection after organ transplantation and autoimmune diseases of tumor high-risk groups.

The present invention discloses a gene function association network-based method for discovering a chronic disease mechanism and an early warning intervention policy thereof. The method can be applied to the field of related research and application of biology, medicine and pharmacy. Epigenetic changes of the high-risk groups surveyed and discovered according to epidemiology before disease attack are detected, the epigenetic changes before the disease is associated with indicator gene changes of the disease through gene function network analysis, then a long-term molecular mechanism contributing to the disease risk is discovered, and risk early warning for the group, risky diagnosis for an individual, and indicators and methods for preventive intervention are provided. According to the method, a long-term steady biological path or biological function change may leave a mark on related gene epigenetic inheritance, and a chronic disease biological path or biological function level mechanism may be found through analysis of the synergistic effect of epigenetic differences.

The invention belongs to the technical field of cardio cerebrovascular rehabilitation training, and discloses a cardio cerebrovascular rehabilitation training system. The cardio cerebrovascular rehabilitation training system comprises: a blood-pressure detecting module, a pulse detecting module, a heart rate detecting module, a main control module and a training module, an analysis module, a disease warning module, a data storage module, and a display module. The system can well group the populations of the Chinese people with cardio cerebrovascular diseases based on the similarity analysis through the analysis module, and carry out targeted personalized rehabilitation treatment for different risk groups as early as possible; the disease warning module is used to timely warn and monitor the risk factors of high risk patients with cardio cerebrovascular diseases, so as to achieve timely and effectively interfere the high-risk groups.

The invention especially relates to molecular markers, internal reference genes and application thereof, a detection kit and a method for constructing a detection model, belonging to the field of biotechnology. With follow-up information used for comparison, the kit provided by the invention has accuracy of 70% in predication of the risk of recurrence or death of first-visit patients with ER-positive and PR-positive breast cancers in 3-10 years after operations, wherein the prediction accuracies of a low-risk group and a high-risk group are 81.1% and 54.4%, respectively while the prediction accuracies of corresponding FFPE pathological examination results are 71.9 to 56.8%, respectively. The risk prediction model matching with the kit only needs the Ct values of the molecular markers, theage of a patient, the stage of pT and the number of LN and does not depend on other clinical pathological information, so the risk prediction model has better performance in evaluation of prognosis ofbreast cancers than simple pathological prediction results, can reduce malpractice caused by errors in pathological prediction and further improves a technical method for evaluation of prognosis of breast cancers.

The invention belongs to the technical field of biology and particularly relates to an application of hsa_circ_0049154 as a prostatic cancer molecular target in preparation of a drug and a kit. The nucleotide sequence of hsa_circ_0049154 is shown in SEQ ID NO.1. The application comprises an application of the prostatic cancer molecular target in screening a drug for preventing, relieving and / or treating prostatic cancer, an inhibitor of the prostatic cancer molecular target and an application of the inhibitor in preparing a drug for preventing, relieving and / or treating prostatic cancer, a prostatic cancer diagnosis kit containing the prostatic cancer molecular target as well as an application of the prostatic cancer molecular target and the diagnosis kit in screening, diagnosis, treatment, situation monitoring and prognosis monitoring of high-risk groups of prostatic cancer. When used for diagnosing the prostatic cancer, the molecular target and the diagnosis kit containing the molecular target have the characteristics of being simple to operate, convenient in material taking, safe, free from wound, higher in specificity and sensitivity and capable of facilitating mass screening.

The invention discloses a mood training usage method and device. The method comprises the steps of: acquiring one or more physiological data of a user through a physiological data acquirer; receiving physiological information and / or psychological information (of the user) input by the user; according to the one or more physiological data, the physiological information and / or psychological information, determining a training mode for training moods of type 2 diabetic patients or a type 2 prediabetic-phase high-risk crowd, wherein the training mode comprises training scenes, training patterns and training methods; and conducting mood training on the user by using the training scenes, the training patterns and the training methods. According to the mood training usage method and device, the mood of the user can be effectively improved.

The invention establishes a single-tube multi-primer mini-pool (MP) human immunodeficiency virus (HIV) nucleic acid test (NAT) technology with combination of RNA (ribonucleic acid) reverse transcription-polymerase chain reaction (RT-PCR) and nested PCR, which is applied in men who have sex with men (MSM) and other high-risk groups for detection during the window period.

The invention provides a kit for detecting senile macular degeneration disease, comprising a related reagent selected freely from rs1061170 variation of exon 9, rs1329428 variation of intron 15, rs800292 variation of exon 2 used for detecting CFH gene and / or rs3753394 variation in a 5' non-coding region used for AMD screening diagnosis. By detecting whether the above locus has variation or not, the kit can detect that risk of senile macular degeneration disease has high association with AMD, and can be used for monitoring and detecting AMD high risk group at an early stage so as to implement early-stage prevention and curing and reduce vision damage to AMD high risk group.

The invention relates to a kit for detecting susceptibility gene SNP locus of nasopharynx cancer, which is realized through the steps as follows: detecting a PCR amplimer and a single-base extension primer of an SNP locus rs2860580 of a susceptibility gene CDKN2A-CDKN2B of nasopharynx cancer; detecting PCR amplimers and single-base extension primers of SNP loci rs1572072 and rs9510787 of a susceptibility gene TNFRSF19 area of nasopharynx cancer; detecting PCR amplimers and single-base extension primers of SNP loci rs28421666,rs2860580 and rs2894207 of a susceptibility gene HLA of nasopharynx cancer; and detecting a PCR amplimer and a single-base extension primer of an SNP locus rs6774494 of a susceptibility gene MDS1-EVI1 of nasopharynx cancer. The kit provided by the invention can be used for simultaneously detecting the SNP loci of a plurality of susceptibility genes of nasopharynx cancer, and provides reference for estimating risk degree of individuals affected by nasopharynx cancer, general survey of populations with high nasopharynx cancer incidence, screening of high risk group attacked by nasopharynx cancer and implementation of relative precautionary measures.

The invention is applicable to the technical field of medical treatment, and provides blood vessel wall plaque recognition equipment, system and method and a storage medium. The method comprises the following steps of identifying patches in the MRI image by using a deep learning method. adopting a deep learning method to identify the blood vessel wall plaque. manpower can be greatly reduced, the plaque identification accuracy is improved, the identification efficiency is improved, and the identification accuracy can be ensured. MRI is adopted to carry out comprehensive and accurate image assessment on ischemic stroke related vascular bed plaques, artificial intelligence is utilized to carry out rapid and accurate diagnosis, and the method has very important significance in screening cerebral stroke high-risk groups and exploring pathogenesis to prevent reoccurrence.

The invention provides a chronic kidney disease screening method and system, and particularly relates to a machine learning method for constructing a chronic kidney disease screening model, which comprises the steps of establishing an effective chronic kidney disease screening model, arranging user data to be screened, substituting the user data to be screened into the chronic kidney disease screening model for model calculation, and finally obtaining a kidney disease risk result. Therefore, the chronic kidney disease screening system is efficient, low in cost and high in accuracy. According to the method, a machine learning BP neural network, XGBoost and a random forest integration algorithm are adopted to train a chronic kidney disease screening model; high-risk groups with chronic kidney diseases can be automatically screened out according to basic body measurement information, symptom information, medical examination information, family history, past history, living habits and other data, and the accuracy reaches up to 0.96 or above.

The invention discloses a micro-RNA-21 ultra-sensitive detection method based on double-enzyme signal cascade amplification. The method includes the steps: horseradish peroxidase enzyme-labeled probepreparation: coupling carboxylation polystyrene micro-spheres and horseradish peroxidase enzyme through DNA (deoxyribonucleic acid) single chains by an EDC (ethylene dichloride) carboxyl and amino coupling method; double-chain specific nuclease assisted target recycling: specifically cutting the DNA single chains complementarily paired with RNA (ribonucleic acid) to be detected in a probe by double-chain specific nuclease, triggering target circular reaction, releasing more horseradish peroxidase enzyme by cutting and amplifying signals; horseradish peroxidase enzyme signal amplification: collecting the horseradish peroxidase enzyme released in supernatant by cutting, adding a TMB (tetramethylbenzidine) chromogenic substrate, realizing naked-eye qualitative diagnosis by color change, and realizing enzyme-labeled quantification according to change of absorbance values. The difference of micro-RNA family members is effectively distinguished, and the method is suitable for community tumorscreening of high risk groups and has great application values in biomedical research and clinical diagnosis.

The invention discloses an application method of serum Exosomes derived long no-coding RNA (long no-coding RNA, LncRNA) LINC00470, namely, serum Exosomes derived long no-coding RNA LINC00470 is used for preparing prognosis preparations for the screening and early diagnosis of high-risk groups with glioma and patients with glioma. Reaches prove that RNA is extracted after Exosomes are separated from serums of patients with glioma, and through carrying out reverse transcription and real-time fluorescent quantitative analysis on the RNA, a situation that the expression level of LncRNA LINC00470 is lowered is found. According to the invention, the specificity of the serum Exosomes LncRNA LINC00470 to the early diagnosis of glioma can reach 85.7%, and the sensitivity can reach 94.1%. By testing the expression level of LncRNA LINC00470 in serum Exosomes of patients with glioma, an early and rapid noninvasive diagnosis on the patients with glioma is implemented.

The invention belongs to the technical field of biologics and particularly discloses the application of hsa_circ_0012755 as a prostatic cancer molecular target in preparing a medicine and a kit. hsa_circ_0012755 has a nucleotide sequence of SEQ ID NO.1 as shown in the specification. The invention discloses the application of the prostatic cancer molecular target in preparing medicines for screening, preventing, relieving and / or treating prostatic cancer, an inhibitor with the prostatic cancer molecular target, the application of the inhibitor in preparing medicines for preventing, relieving and / or treating prostatic cancer, a prostatic cancer diagnosis kit with the prostatic cancer molecular target, and the application of the prostatic cancer molecular target and the diagnosis kit in screening, diagnosis, treatment, situation monitoring and prognosis monitoring of high risk groups of prostatic cancer. When being adopted for prostatic cancer diagnosis, the molecular target and the diagnosis kit with the molecular target are simple to operate, convenient in material obtaining and safe and noninvasive, and in addition have the characteristics of being high in specificity and sensitivity and easy in large-scale screening.

The invention relates to a movable pathogen nucleic acid testing laboratory system supporting rapid deployment. Three main steps of reagent storage and preparation, specimen preparation, amplificationand product analysis involved in a nucleic acid testing process are independently arranged in three movable structures respectively; the isolation requirements among the three steps in the nucleic acid testing process are met, meanwhile, the three movable structures can be quickly moved and deployed to any required position and unfolded to form a pathogen nucleic acid testing laboratory with a complete function, detection is executed on site at the key prevention and control position, and centralized transfer of high-risk groups is avoided.